Two recent medical studies presented at the 34th Annual Meeting of the European Bone and Infection Society in September confirmed the efficacy of BONESUPPORT's CERAMENT|G in the management of osteomyelitis in infected diabetic foot.
Here are five key points:
1. CERAMENT|G is an antiobiotic eluting bone substitute technology that release Gentamicin.
2. It is the first approved antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of bone infections.
3. Contiguous bone infection is a common complication of diabetic foot ulcers, and approximately 20 percent of patients with a diabetic foot infection have underlying osteomyelitis.
4. Diabetes is the most common cause of non-traumatic lower limb amputation, with approximately 30 percent of patients with a diabetic foot ulcer leading to amputation.
5. BONESUPPORT is a company focused on injectable bone graft substitute for orthopedics and trauma focusing on bone infection, instrument augmentation and spinal applications.